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We report 3 cases of gastric carcinoids with hypergastrinemia. Case 1: A 60-year-old man had a 2cm carcinoid of the stomach and
underwent partial resection. Involvement of the muscularis propria and lymph nodes metastasis were observed microscopically.
Follow-up gastroscopy revealed another carcinoid lesion and total gastrectomy was performed. Case 2: A 67-year-old woman with
multiple carcinoids of the entire stomach underwent antrectomy. No growth of residual tumors has been detected so far. Case 3:
A 61-year-old man had a tumor near the esophagogastric junction and underwent total gastrectomy. Carcinoid component was
diﬀusely intermingled with adenocarcinoma in the tumor and invaded into the subserosa. In all 3 cases, the serum gastrin level
was high and atrophic gastritis was microscopically observed. Carcinoid tumor in Case 3 was diﬀerent from those in Cases 1 and
2 and interestingly, gastric carcinoid with hypergastrinemia showed various types of appearance.
1.Introduction
Gastric carcinoids originate from the foregut and are derived
from enterochromaﬃn-like (ECL) cells, which are the main
neuroendocrine cells in the gastric mucosa. Gastrin acts
directly on ECL cells to induce hyperplasia, dysplasia, and,
eventually, neoplasia or carcinoid [1]. In patients with
chronic atrophic gastritis, decreased gastric acid secretion
stimulates the secretion of gastrin, and ECL cells transform
into a carcinoid. In this paper, we present 3 cases of gastric
carcinoids in atrophic gastritis with hypergastrinemia. One
patient had a relatively large tumor with lymph node
metastasis, another patient had multifocal small tumors,
and the third patient had a large tumor mixed with poorly
diﬀerentiated adenocarcinoma. A gastric carcinoid with
hypergastrinemia is usually small, multiple, and located
within the mucosa or submucosa. We experienced 3 diﬀerent
types of gastric carcinoids.
2. Case Presentation
Case 1. A60-year-oldman,whosuﬀeredfromcerebralpalsy
due to measles encephalopathy at the age of 6 months,
became unable to eat and underwent gastroscopy. A round
tumor was detected at the anterior wall of the middle gastric
body,andbiopsyrevealedacarcinoid(Figure1(a)).Noother
p o l y p o i dl e s i o n sw e r ed e t e c t e d .T h el e v e lo fs e r u mg a s t r i n
was very high (4100pg/mL (normal range: <200pg/mL))
and the antiparietal cell antibody test was positive. No
gastrin-producing tumor was detected by radiologic exam-
ination. Because of his poor activity of daily life and benign
nature of the carcinoid, his family did not agree any surgical
treatment, and endoscopic resection was ﬁrst considered;
however the tumor was too large to be removed endoscop-
ically. Due to the persistent symptom, they accepted only a
reduced surgery, and partial resection of the stomach was
performed and metastatic lymph nodes were dissected. The
tumor was 2cm in diameter (Figure 1(b)) with involvement
of the muscularis propria (Figure 2(a)). These uniform cells
(Figure 2(b)) were strongly positive for chromogranin A
and synaptophysin (Figures 2(c) and 2(d)). High lymphatic
permeation was observed. Seven months later, follow-up
gastroscopy revealed another polypoid lesion in the residual
stomach (Figure 3(a)). The biopsy revealed a carcinoid
and hypergastrinemia was persistent. Total gastrectomy
was performed (Figure 3(b)), and microscopic evaluation
showed numerous endocrine cell micronests (ECMs; size:
0.1∼1.75mm),whichwerediﬀuselyobserved inthestomach2 Case Reports in Medicine
(Figure 3(c)). Regional lymph node metastasis was observed
again. The gastric mucosa was diagnosed as compatible with
type A atrophic gastritis. Mucosal atrophy was evident in the
fundus but not in the antrum. The level of serum gastrin
became within normal range.
Case 2. A 67-year-old woman experienced epigastric pain
and nausea for the past 2 months. Gastroscopy revealed
lots of elevated lesions (all were less than 5mm in diam-
eter) in the whole stomach (Figure 4(a)), and the biopsy
showed a carcinoid. She was recommended to undergo total
gastrectomy and was referred to our department. On the
basis of a very high level of serum gastrin (>3000pg/mL),
positive antiparietal cell antibody test, and atrophic gastritis
(which was observed macroscopically and microscopically),
we diagnosed her condition as typical type 1 carcinoid
and performed antrectomy. Pathological analysis showed
that the resected tissue was a carcinoid (Figure 4(b))w i t h
invasion into the submucosa (Figure 4(c)). The tumor
cells were positive for chromogranin A (Figure 4(d))a n d
synaptophysin. Type A gastritis was observed under the
background of gastric mucosa of the antrectomy specimen,
which was characterized by atrophic gastric glands of gastric
body and decreased number of parietal cells (Figure 5(a)).
In the mucosa of antrum, no apparent atrophy of the
pyloric glands (Figure 5(b)) and hyperplasia of gastrin-
producing cells were detected (Figure 5(c)). After surgery,
serum gastrin level immediately decreased to the normal
range. More than 12 months have passed since antrectomy,
and no apparent growth of the residual tumors has been
detected by gastroscopy so far.
Case 3. A 61-year-old man was asymptomatic except for
severe anemia (Hb: 4.5g/dl) that was detected at a medical
checkup. Gastroscopy revealed a large gastric tumor near
the esophagogastric junction (Figure 6(a)), and biopsy
showed poorly diﬀerentiated adenocarcinoma with ECL cell
tumor (carcinoid). The level of serum gastrin was high
(570pg/mL) and the anti-parietal cell antibody test was
negative. After blood transfusion, total gastrectomy was
performed (Figure 6(b)) with regional lymphadenectomy.
Histological examination of the resected specimen revealed
that the tumor was composed of poorly diﬀerentiated
adenocarcinoma (Figure 7(a)) with components of ECL cell
tumors (Figure 7(b)). These ECL cell tumors were diagnosed
as carcinoid because they were immunohistochemically pos-
itive for chromogranin A (Figure 7(c)) and synaptophysin,
and the cell size was larger than small cell carcinoma. The
carcinoid diﬀusely intermingled with adenocarcinoma and
invaded into the subserosa (Figure 7(d)). Only adenocarci-
noma cells were detected in the metastatic regional lymph
nodes. The gastric mucosa was diagnosed as compatible with
type A atrophic gastritis.
3. Discussion
A gastric carcinoid is a relatively rare neoplasm. Previously,
carcinoids have been classiﬁed according to the embryologic
origin (hindgut, midgut, and foregut); a gastric carcinoid
originates from the foregut. Recently, carcinoids have been
categorized according to their pathobiological behaviors into
3d i ﬀerent types [2]. Type 1 carcinoid is the most common
type; it arises in patients with chronic atrophic gastritis
(type A gastritis) under hypergastrinemic conditions. Type 2
carcinoid is the least common type; it occurs in patients with
gastrinoma Zollinger-Ellison syndrome (ZES) who have also
beendiagnosedwithmultipleendocrineneoplasiasyndrome
type-I (MEN-I). Type 3 carcinoid occurs sporadically and is
not associated with atrophic gastritis or hypergastrinemia;
the tumor is usually a single and large tumor and has the
most malignant potential among these 3 types of carcinoids.
Herein, we report 3 cases of gastric carcinoids. In case 1,
the tumor was 2cm in diameter and invaded the muscularis
propria and caused lymph node metastasis. In case 2, the
tumors were multiple and small, and in case 3, a carcinoid
and adenocarcinoma intermingled in a single tumor that
invaded the subserosa. All cases were concomitant with
hypergastrinemiaandatrophicgastritis.Wecategorizedcases
1 and 2 as type I carcinoid and case 3 as a carcinoid-
carcinoma tumor.
A type 1 gastric carcinoid is usually small, multifocal,
and located in the gastric fundus with a low potential
of malignancy [3]. It grows slowly, and the prognosis is
similar to that of the general population. The 5-year survival
rate is around 95% [4, 5]. Due to its benign course,
the recommended treatment ranges from medical therapy
and endoscopic resection with strict follow-up to surgical
excision. Gilligan et al. proposed a decision tree for the
management of gastric carcinoids [6]. More recently, Borch
et al. made recommendations for the treatment of type 1
carcinoids: radical endoscopic removal should be performed
for patients with up to 5 tumors with a maximum diameter
of 10 mm, and antrectomy should be performed for patients
with more than 5 tumors with a maximum diameter of 10
mm [4] (referred in the ENETS guidelines [7]). If the tumors
are larger than 10mm (regardless of number), antrectomy
was recommended with surgical excision of tumors larger
than 10mm. If the serosa is involved or the tumor has
spread outside the stomach, total gastrectomy with lymph
node dissection was advised. Hou et al. suggested that total
gastrectomy might be necessary if tumors recurred after
antrectomy [8].
There seems to be some diﬀerences in the characteristics
of type 1 gastric carcinoids based on Japanese and Western
reports. The incidence of gastric carcinoids is 2.4%−8.7%
[9] among all cases of gastrointestinal tract carcinoids in
Western countries whereas it is 27.3% in Japan [10]. The
prevalence of type 1 gastric carcinoids in Western reports
has been around 80% [4, 5, 11]. However, Iwashita reported
that type 1 gastric carcinoids accounted only for 35% (25
out of 72 cases) of all cases of gastric carcinoids in Japan
[12]. In these 25 cases, all lesions were within the mucosa or
submucosa. The rate of lymph node metastasis was 25% and
was much higher than that reported in the Western literature
(0%−5.9%) [4, 5, 11]. Therefore, Iwashita et al. concluded
that the malignant potential of type 1 carcinoids was not
as low as it was believed. According to the Western reports,Case Reports in Medicine 3
(a) (b)
Figure 1: (a) Gastroscopy showed a round tumor at the anterior wall of the gastric body. (b) The resected tumor was 2cm in diameter.
(a) (b)
(c) (d)
Figure 2: (a) Histological examination of the partially resected tumor revealed carcinoid with muscularis propria involvement (H&E ×4).
(b) Carcinoid was consisted of uniform cells with round-shaped nuclei with ribbon-like structure (H&E ×40). (c), (d) The tumor cells
showed immunoreactivity for synaptophysin (synaptophysin, (c) ×4, (d) ×40).
the rate of tumor invasion into the muscularis propria was
3.4%−9.0% and that into the subserosa was 0%−5.9% [4, 5,
11]. In our study, case 1 showed invasion into the muscularis
propria with lymph node metastasis, and case 3 showed
inﬁltration of the subserosa. However, both ﬁndings were
relatively rare.
In Japan, total gastrectomy with lymph node dissection
hasbeenthepreferredsurgicalprocedureformultiplegastric
carcinoids associated with type A gastritis. The merit of
this procedure is that the fundic gland area, which could
be the origin of the carcinoid and ECM, is completely




Figure 3: (a) Follow-up gastroscopy revealed another polypoid lesion in the residual stomach. (b) Resected whole stomach. (c) Numerous
endocrine cell micronests (arrows) were observed widely in the muscularis mucosae of the stomach (H&E, ×4).
(a) (b)
(c) (d)
Figure 4: (a) Gastroscopy revealed multiple elevated lesions at the whole stomach. (b) Pathological analysis of the tumors after antrectomy
showed carcinoid consisted of uniform cells with round-shaped nuclei with rosette-like or nodular solid structure (H&E ×40), (c) with
submucosal invasion (H&E ×4). (d) The tumor cells were positive for chromogranin A staining (chromogranin A ×4).
Okada et al. also suggested that total gastrectomy should
be considered as one of the treatments for multiple gastric
carcinoids with hypergastrinemia [13]. In case 2, the patient
was recommended to undergo total gastrectomy to remove
all tumors. However, we chose antrectomy since it was a
typical type 1 gastric carcinoid. ECL cell hyperplasia may
be reversible if hypergastrinemia is abolished. Therefore,
antrectomy or surgical excision of the majority of the G
cells can be an appropriate treatment [14]. The level of
serum gastrin actually decreased within normal range after
antrectomy in case 2. Some researchers observed the spon-
taneous regression of residual carcinoids after antrectomy
[4]. However, not all patients experienced tumor regression
[15].OnereasonforthatobservationwasspeculatedtobeanCase Reports in Medicine 5
(a) (b) (c)
Figure 5: Background gastric mucosa of the resected stomach was type A gastritis microscopically. (a) Atrophy of gastric glands in the
mucosa of gastric body was shown (H&E ×4). (b) In the mucosa of antrum, no apparent atrophy of the pyloric glands was observed (H&E
×4). (c) Hyperplasia of gastrin-producing cells was detected (arrows) (gastrin staining ×4).
(a)
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(b)
Figure 6: (a) Gastrcosopy revealed a large gastric tumor near the esophagogastric junction. (b) Total gastrectomy was performed, and the
resected tumor was approximately 8cm in diameter.
autocrine eﬀect that is present in ECL cells after malignant
transformation [16]. Therefore, strict follow-up should be
scheduled.
Some authors have recommended a conservative
approach without removal of the tumors. Hosokawa et al.
proposed a follow-up program without surgical resection
for multiple gastric carcinoids that are associated with
type A gastritis [17]. They reported 8 patients who were
free of growth or metastasis for a maximum of 10.8 years
despite persistent hypergastrinemia. They suggested that
such patients could be followed up with periodic endoscopic
examination if their tumors are smaller than 2cm in
diameter.
In the present study, we observed atrophic gastritis in all
3 cases. The development of adenocarcinoma or endocrine
tumors in atrophic gastritis is widely documented [18]. In
case 3, the ECL cell component was focally mixed with
poorly diﬀerentiated adenocarcinoma in one tumor. It may
be controversial to diagnose these ECL cell components as
carcinoid; however, they were immunohistochemically posi-
tive for chromogranin A and synaptophysin, and the cell size
w a st o ol a r g et ob ed i a g n o s e da ss m a l lc e l lc a r c i n o m a .T h e r e
have been some reports of carcinoma with interspersed
carcinoid, and such a tumor is sometimes referred to as a
composite tumor and its occurrence is relatively rare [18].
This phenomenon supports the concept that adenocarci-
noma (epithelial) and carcinoid (neuroendocrine) cells can
be diﬀerentiated from a multipotent multidirectional stem
cell.Wespeculatethathighserumgastrinlevelcontributedto
this neuroendocrine diﬀerentiation. Longstanding hypergas-
trinemiamayhaveplayedacausativeroleinthedevelopment
of carcinoid and cancer [19]. From this viewpoint, long-
acting somatostatin analogs which suppressed gastrin pro-
duction and reported eﬀective in type 1 carcinoid [20], can
be used to slow the malignant change. Another possibility
of carcinoid-adenocarcinoma coexistence is that carcinoid
releases some growth factors which stimulate gastric mucosa
and cause malignant transformation [21]. Moreover, during
chronic inﬂammation at the gastric mucosa, secreted factors
such as lymphokines and prostaglandins modulate gastric
epithelia, resulting in carcinoid and adenoartinoma [22].
We showed 2 cases of multiple gastric carcinoids and 1
case of a carcinoid-adenocarcinoma tumor. All 3 cases were
diagnosed with atrophic gastritis, which is associated with an
increased risk of gastric carcinoma. We could have selected
antrectomy with wedge resection of the large tumor for case6 Case Reports in Medicine
(a) (b)
(c) (d)
Figure 7: (a), (b) Microscopic ﬁndings of the resected specimen revealed that the tumor was comprised of poorly diﬀerentiated
adenocarcinoma ((a) H&E ×40) with components of ECL cell carcinoid ((b) H&E ×40). (c) Carcinoid, immunohistochemically positive
for chromogranin A staining (arrows), diﬀusely intermingled with adenocarcinoma (chromogranin A ×4). (d) Both carcinoid and
adenocarcinoma invaded to subserosa (H&E ×4).
1andwechoseitforcase2.Asshowninthepreviousstudies,
larger (>10mm in diameter) or deeper inﬁltrating (than
submucosa) tumors may, although rarely, be associated with
regional lymph node metastasis, [10, 12]ap r o g n o s t i cf a c t o r
oftype1carcinoid[4].Withintensivefollow-uponthesmall
residual carcinoids and the stomach after surgery, we believe
that antrectomy (with lymph node dissection in the risky
case such as case 1) is a good treatment option regarding the
postoperative quality of life.
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